Our top pick for
CryoLife Inc is a medical devices business based in the US. CryoLife shares (CRY) are listed on the NYSE and all prices are listed in US Dollars. CryoLife employs 1,200 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$21.04|
|52-week range||$16.60 - $32.34|
|50-day moving average||$22.94|
|200-day moving average||$26.03|
|Wall St. target price||$33.44|
|Dividend yield||$0.03 (0.14%)|
|Earnings per share (TTM)||$-0.31|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||-0.14%|
|1 month (2021-09-24)||-9.39%|
|3 months (2021-07-26)||-18.76%|
|6 months (2021-04-26)||-11.04%|
|1 year (2020-10-26)||10.97%|
|2 years (2019-10-25)||-12.15%|
|3 years (2018-10-26)||31.39|
|5 years (2016-10-26)||25.99%|
Valuing CryoLife stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CryoLife's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
CryoLife's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 420.8333. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into CryoLife's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
CryoLife's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $40.2 million.
The EBITDA is a measure of a CryoLife's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$280.3 million|
|Operating margin TTM||6.11%|
|Gross profit TTM||$167.8 million|
|Return on assets TTM||1.42%|
|Return on equity TTM||-3.89%|
|Market capitalisation||$827.5 million|
TTM: trailing 12 months
There are currently 3.4 million CryoLife shares held short by investors – that's known as CryoLife's "short interest". This figure is 3.5% down from 3.5 million last month.
There are a few different ways that this level of interest in shorting CryoLife shares can be evaluated.
CryoLife's "short interest ratio" (SIR) is the quantity of CryoLife shares currently shorted divided by the average quantity of CryoLife shares traded daily (recently around 152443.46463742). CryoLife's SIR currently stands at 22.34. In other words for every 100,000 CryoLife shares traded daily on the market, roughly 22340 shares are currently held short.
However CryoLife's short interest can also be evaluated against the total number of CryoLife shares, or, against the total number of tradable CryoLife shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CryoLife's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 CryoLife shares in existence, roughly 90 shares are currently held short) or 0.1089% of the tradable shares (for every 100,000 tradable CryoLife shares, roughly 109 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against CryoLife.
Find out more about how you can short CryoLife stock.
We're not expecting CryoLife to pay a dividend over the next 12 months.
CryoLife's shares were split on a 3:2 basis on 27 December 2000. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your CryoLife shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for CryoLife shares which in turn could have impacted CryoLife's share price.
Over the last 12 months, CryoLife's shares have ranged in value from as little as $16.6 up to $32.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while CryoLife's is 1.5688. This would suggest that CryoLife's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.